CD19 and acute lymphoblastic leukemia: Interestingly, the same group of investigators further showed LILRB1 as a biomarker for CD19-B-ALL in post-CD19 directed therapy relapsed disease [12], highlighting the utility of LILRB1 in MRD detection.